From Oncology Nursing News: "Q&A: Transitioning Myeloma Care to the Community Level" Read more about From Oncology Nursing News: "Q&A: Transitioning Myeloma Care to the Community Level"Add new comment
Bipartisan Cancer Drug Parity Act Reintroduced to Lower Costs for Oral Cancer Drugs Read more about Bipartisan Cancer Drug Parity Act Reintroduced to Lower Costs for Oral Cancer DrugsAdd new comment
European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma Read more about European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma Add new comment
Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma Patients Read more about Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma PatientsAdd new comment
June 2025 – Myeloma News from the Journals Read more about June 2025 – Myeloma News from the JournalsAdd new comment
The International Myeloma Society and the IMF’s International Myeloma Working Group collaborate on Consensus Definition of High-Risk Multiple Myeloma Read more about The International Myeloma Society and the IMF’s International Myeloma Working Group collaborate on Consensus Definition of High-Risk Multiple MyelomaAdd new comment
International Myeloma Foundation (IMF) Honors 2025 Kyle and Durie Achievement Awardees, Dr. Sagar Lonial and Dr. Sonja Zweegman Read more about International Myeloma Foundation (IMF) Honors 2025 Kyle and Durie Achievement Awardees, Dr. Sagar Lonial and Dr. Sonja Zweegman Add new comment
From Clinical Research News: Many Approaches Collectively Aim at a Cure for Myeloma Read more about From Clinical Research News: Many Approaches Collectively Aim at a Cure for MyelomaAdd new comment
Important New Data and Results from Myeloma Research Trials Unveiled at ASCO 2025 Read more about Important New Data and Results from Myeloma Research Trials Unveiled at ASCO 2025Add new comment
CHMP of the European Medicines Agency Recommends Approval of Blenrep (belantamab mafodotin) for Relapsed/Refractory Multiple Myeloma Read more about CHMP of the European Medicines Agency Recommends Approval of Blenrep (belantamab mafodotin) for Relapsed/Refractory Multiple Myeloma Add new comment
